ライフサイエンスコーパス: homovanillic

1 Tissue levels of DA metabolites homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic ac

2 binding potential (BP) with plasma levels of homovanillic acid (HVA) and clinical symptoms.

3 ns of dopamine, and the dopamine metabolites homovanillic acid (HVA) and dihydroxyphenylacetic acid (

4 , 3-4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) and in the DOPAC/dopamine ratio

5 3, 4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) by 76%, 53% and 40%, respectivel

6 s 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in caudate nucleus resulting fro

7 The average percentage of labeled homovanillic acid (HVA) in lumbar cerebrospinal fluid (C

8 kg i.p.) 15 min prior to sacrifice increased homovanillic acid (HVA) levels in the left medial prefro

9 of greater than 10 points and an increase in homovanillic acid (HVA) or 5-hydroxyindoleacetic acid (5

10 CSF concentration of homovanillic acid (HVA) was significantly lower in the L

11 Levels of the dopamine metabolite homovanillic acid (HVA) were decreased in severely affec

12 SF concentrations of the dopamine metabolite homovanillic acid (HVA) were determined in 30 recently a

13 ne (DA), dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-H

14 CSF homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-H

15 triatal tissue punches were analyzed for DA, homovanillic acid (HVA), and DA activity (HVA/DA) using

16 sma levels of fenfluramine, norfenfluramine, homovanillic acid (HVA), cortisol, and prolactin were de

17 SF) concentration of the dopamine metabolite homovanillic acid (HVA), in an extended inbred vervet mo

18 ions of 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), or 3-methoxy-4-hydroxyphenylgyc

19 , 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), were elevated over the same tim

20 , 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), were found to be decreased by >

21 the main metabolites, followed by DOPAC and homovanillic acid (HVA).

22 , 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA).

23 , 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA).

24 ites, 3,4-dihydroxyphenylalanine (DOPAC) and homovanillic acid (HVA); norepinephrine (NE) and its met

25 [3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)] levels and tyrosine hydroxylase

26 Plasma homovanillic acid (HVA, a dopamine metabolite), adrenoco

27 alyzed cerebrospinal fluid concentrations of homovanillic acid (the major catabolite of dopamine) and

28 The homovanillic acid : dopamine ratio, a metabolic index, i

29 ydroxyindoleacetic acid [5-HIAA]), dopamine (homovanillic acid [HVA]), and norepinephrine (3-methoxy-

30 s well as regulated the dopamine metabolites homovanillic acid and dihydroxyphenylacetic acid.

31 of tetrahydrobiopterin (BH4), neopterin, and homovanillic acid and low levels of tyrosine hydroxylase

32 30, 1994, were eligible for urinary assay of homovanillic acid and vanillylmandelic acid at 3 weeks a

33 CSF homovanillic acid did not correlate with plasma total ch

34 of dopamine, 3,4-dihydroxybenzoic acid, and homovanillic acid in GSHPx knock-out mice than those see

35 or no response to L-dopa, and low levels of homovanillic acid in the central nervous system.

36 stored the decreased content of dopamine and homovanillic acid in the nigrostriatal neurons of the ag

37 The CSF 5-hydroxyindoleacetic acid and homovanillic acid levels did not correlate significantly

38 Homovanillic acid levels in 16 (89%) of 18 patients and

39 3-methoxy-4-hydroxyphenylethyleneglycol and homovanillic acid levels in the treatment groups.

40 3-methoxy-4-hydroxyphenylethyleneglycol and homovanillic acid levels.

41 ograms and urinary vanillylmandelic acid and homovanillic acid measurements were performed during a 9

42 ystonia during treatment, growth hormone and homovanillic acid measures, psychotic symptom activation

43 While neither homovanillic acid nor xanthine concentrations differenti

44 All children had raised ratios of homovanillic acid to 5-hydroxyindoleacetic acid in cereb

45 catecholamine values, or an increase in the homovanillic acid to vanillylmandelic acid ratio greater

46 Homovanillic acid was found to be a suitable fluorogen i

47 of D-cycloserine, relevant amino acids, and homovanillic acid were assayed at baseline and at weeks

48 dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid were comparable in the young and aged

49 ine metabolites (5-hydroxyindoleacetic acid, homovanillic acid, and 3-methoxy-4-hydroxyphenethylenegl

50 acetic acid, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 3-methoxytyramine in addition to

51 the metabolites 3,4-deoxyphenylacetic acid, homovanillic acid, and 5-hydroxyindoleacetic acid were m

52 Aspects of the interaction among thiols, homovanillic acid, and peroxidase are discussed which li

53 ebrospinal fluid 5-hydroxyindoleacetic acid, homovanillic acid, and tryptophan concentrations.

54 abolites, 3,4-dihydroxyphenylacetic acid and homovanillic acid, as found in the striatum.

55 CSF measures of 5-hydroxyindoleacetic acid, homovanillic acid, dehydroepiandrosterone, or pregnenolo

56 The strongest ligands, such as homovanillic acid, eugenol, and methyl vanillate all con

57 metabolites, dihydroxyphenylacetic acid and homovanillic acid, increased in the auditory forebrain b

58 bolism to 3,4-dihydroxyphenylacetic acid and homovanillic acid, our results indicate that Met homozyg

59 ds (PCLCs): vanillic acid, isovanillic acid, homovanillic acid, syringic acid, syringaldehyde, feruli

60 tion and lower levels of cerebrospinal fluid homovanillic acid.

61 ephrine, 3-methoxy-4-hydroxyphenylgycol, and homovanillic acid.

62 For controls, the mean [xanthine]/[homovanillic acid] quotient was 13.1+/-5.5 as compared t

63 The [xanthine]/[homovanillic acid] ratio also increased between the firs

64 The [xanthine]/[homovanillic acid] ratio in the Parkinson's disease subj